A5050860383- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gastric Cancer Management and Outcomes
- Frailty in Older Adults
- Esophageal Cancer Research and Treatment
- Medical Imaging and Pathology Studies
- Salivary Gland Tumors Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Tracheal and airway disorders
- melanin and skin pigmentation
- Brain Metastases and Treatment
- Nutrition and Health in Aging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Sarcoidosis and Beryllium Toxicity Research
- Metastasis and carcinoma case studies
- Immunotherapy and Immune Responses
National Hospital Organization
2017-2023
Toneyama National Hospital
2017-2023
Boehringer Ingelheim (Japan)
2023
Bristol-Myers Squibb (Japan)
2023
Chugai Pharma (United States)
2023
AstraZeneca (Brazil)
2023
Eli Lilly (Japan)
2023
Takeda (Japan)
2023
Novartis (Japan)
2023
Sanofi (France)
2023
BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated maximum duration that on T cells or association between this and residual therapeutic efficacy potential adverse events.
Chemoimmunotherapy is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). However, whether findings from pivotal trials can be extrapolated to clinical practice setting remains unclear.To compare treatment outcome gaps following chemoimmunotherapy ES-SCLC between those who met and did not meet eligibility criteria used in previous trials.A prospective cohort study was conducted September 1, 2019, 30, 2020, at 32 hospitals Japan, least 12 months...
A 43-year-old never-smoking woman presented with a palpable mass in the left breast. Chest radiography and computed tomography revealed 5-cm solitary tumor upper lung field (Fig. 1A, B) multiple mediastinal lymph node enlargements addition to breast tumor. Contrast-enhanced brain magnetic resonance imaging multiple, asymptomatic metastases 1C) skin metastasis scalp. Bone pelvis hepatic were also observed. The resected sections malignant neoplasia organized into either solid nests or...
Pleomorphic carcinoma (PC) of the lung is a rare type non‐small cell cancer, exhibiting aggressive behavior and resistance to chemotherapy radiotherapy. A previous study reported that PCs expressed high levels PD‐L1, suggesting potential efficacy immune checkpoint inhibitors in these tumors. We retrospectively reviewed clinical records three patients with PC treated nivolumab: 59‐year‐old woman (Case 1), 66‐year‐old man 2), an 83‐year‐old 3). PD‐L1 was highly their tumor cells. Two cases...
Abstract Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce. Therefore, we first investigated characteristics associated with shorter durable responses treatment and revealed clinical patterns AR prognosis involved. Methods We conducted a retrospective multi-center cohort study that included NSCLC PD-L1 tumor proportion scores ≥50% who received first-line...
The aim of the present study was to analyze impact metastatic status on prognosis epithelial growth factor receptor (EGFR) mutation-positive patients with non-small cell lung cancer (NSCLC) treated first-generation EGFR-tyrosine kinase inhibitors (TKIs). A total 178 EGFR stage IIIB-IV and relapsed NSCLC who were gefitinib or erlotinib as first-line treatment enrolled in study. Metastatic status, progression-free survival (PFS), overall (OS) treatment-response rates investigated. association...
Abstract To investigate the exposure–safety relationships of afatinib in Japanese population, we performed population pharmacokinetics (PK) analysis advanced non-small cell lung cancer patients harboring epidermal growth factor receptor mutation. Plasma samples were collected at 0.5–1, 2–3, 8–12, and 24 h after oral (40 mg) administration on day 1 8. concentrations determined using high-performance liquid chromatography. Data was analyzed following approach software Phoenix ® NLME TM Version...
Background Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with programed death ligand-1 (PD-L1) expression ≥50%. However, the association between efficacy of pembrolizumab and PD-L1 levels in ≥50% has not been fully elucidated. Methods We retrospectively analyzed NSCLC tumor proportion score (TPS) who received at 11 institutions Japan February 2017 January 2018. Patients were divided into TPS 50–89% 90–100% (ultra-high...
Background Pirfenidone is an antifibrotic agent that potentially effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, no study has reported on its prophylactic value against chemotherapy‐associated acute IPF exacerbations when combined with chemotherapy non‐small cell lung cancer (NSCLC). The present assessed safety and effectiveness pirfenidone carboplatin‐based or immune checkpoint inhibitors (ICIs) in patients NSCLC. Methods A total 14 NSCLC who received from 2013...
Nivolumab is an anti-PD-1 blocking monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed records with NSCLC administered nivolumab therapy at Toneyama National Hospital, Japan, from January 2016 to 2018. Of 87 therapy, five experienced during one cycle therapy. Four were treated corticosteroids...
Abstract Background Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels ≥50% [1]. However, it not all patients, and the factors predicting responses among this population remain unknown. Methods We retrospectively analyzed NSCLC a PD-L1 tumor proportion score (TPS) > 50%, who received monotherapy pembrolizumab from February 1, 2017 to April 30, 2018. The study included 11...
Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy currently the standard for NSCLC, some ICI/Chemo regimens nonsquamous (non-Sq) contain bevacizumab (BEV), which effective controlling MPE may enhance response. This study aimed to determine optimal first-line this clinical population.We retrospectively enrolled consecutive non-Sq who received or...
Although small cell lung cancer (SCLC) is initially sensitive to chemotherapy, it recurs in most cases. Standard regimens for salvage chemotherapy have not been established, and the prognosis of relapsed SCLC remains poor. In present study, we investigated clinical efficacy safety nanoparticle albumin-bound paclitaxel (nab-paclitaxel) treatment SCLC. this retrospective multicenter analysis, 14 patients (3 women 11 men; median age 71 years) with received nab-paclitaxel alone or combination...
The diagnostic yield of peripheral pulmonary lesions (PPLs) by flexible bronchoscopy (FB) is still insufficient. To improve the bronchoscopy, several techniques such as endobronchial ultrasound (EBUS), virtual bronchoscopic navigation (VBN), and rapid on-site evaluation (ROSE) have been examined. primary purpose present study was to evaluate usefulness combining EBUS, VBN, ROSE for diagnosing small PPLs.Patients with PPLs 30 mm or less on chest computed tomography (CT) were prospectively...
A 61-year-old woman with stage IVA lung adenocarcinoma exhibited high PD-L1 expression. Pembrolizumab was administered as second-line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three five courses. subsequently diagnosed fulminant type 1 diabetes mellitus ketoacidosis eighth course insulin treatment initiated. remained effective continued for 21 courses, even after onset mellitus. Immune-checkpoint inhibitor can be...
Abstract Background The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non–small cell lung cancer; however, it is unclear whether the same applicable for small cancer (SCLC). We evaluated second‐line amrubicin (AMR) following first‐line platinum‐based chemotherapy and ICI combination therapy (chemo‐ICI) SCLC. Patients Methods retrospectively enrolled consecutive patients with SCLC treated AMR as a chemo‐ICI...